Novel biomarkers represent a promising means to improve diagnosis of nonalcoholic steatohepatitis (NASH). Currently, a definitive diagnosis requires a liver biopsy, a surgical procedure with many limitations. There are a variety of biomarkers that can assess liver status, but they do not always distinguish between patients with NASH and those …
![](https://ddblog.labcorp.com/wp-content/uploads/2016/04/Covance-NASH-Liver-Disease-Blog-300x300-1.jpg)